美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

避孕概念

2,601.73

+73.512.91%

漲家數：5

跌家數：- -

平家數：- -

市盈率：- -

高：2,615.21

開：2,528.30

低：2,527.87

收：2,528.22

成交量：1,237.87萬

成交額：2.67億

市值：415.18億

流通市值：406.67億

資料載入中...

總覽新聞資訊

梯瓦製藥Austedo®與Austedo XR®數據凸顯遲發性運動障礙治療與護理的長期進展

Veru授予諾和諾德優先談判權，涉及恩諾博沙姆與任何諾和諾德GLP-1產品的聯合療法

梯瓦製藥拓展歐洲生物類似藥版圖推出阿柏西普生物類似藥Ahzantive®

曼恩凱德生物醫療進入數據密集開發階段：完成Inhlo-1研究1B期隨機化並啓動Nintedanib DPI針對IPF患者的Inhlo-2試驗2期首例患者入組

足球——國際足聯推出全球計劃，旨在提升女足運動員的健康水平和競技表現

熱門話題-FDA批准用於兒童的吸入式胰島素後，MannKind股價上漲

美國食品藥品監督管理局批准曼恩康德公司用於兒童的吸入式胰島素

曼恩凱德生物醫療宣佈FDA批准Afrezza®，首個且唯一用於6歲及以上糖尿病兒童及青少年的吸入式餐時胰島素

曼恩凱德生物醫療獲FDA解除對Afrezza的上市後要求

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4584/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"避孕概念","latestPrice":2601.7324,"timestamp":1781207999999,"preClose":2528.2249,"halted":0,"volume":12378652,"delay":0,"changeRate":0.029075,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":73.507568,"latestTime":"06-11 16:00:00 EDT","open":2528.3003,"high":2615.2117,"low":2527.868,"amount":267128792.014878,"amplitude":0.034547,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1781222400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.030903,"peRate":27.482094,"turnoverRate":0.008402,"increases":5,"decrements":0,"flats":0,"marketCap":41517548113,"floatMarketCap":40666903061},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2615.2117,"amplitude":0.034547,"preClose":2528.2249,"low":2527.868,"pbRate":"5.030903","latestPrice":2601.7324,"volume":12378652,"delay":0,"open":2528.3003,"prevYearClose":2379.9924,"prevWeekClose":2550.2698,"prevMonthClose":2639.9878,"prevQuarterClose":2236.9697,"fiveDayClose":2571.2742,"twentyDayClose":2694.5327,"sixtyDayClose":2240.5881,"secType":"PLATE","market":"US","turnoverRate":0.008402,"peRate":27.482094,"marketCap":41517548113,"floatMarketCap":40666903061,"timestamp":1781207999999,"nameCN":"避孕概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1188750222","title":"梯瓦製藥Austedo®與Austedo XR®數據凸顯遲發性運動障礙治療與護理的長期進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1188750222","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188750222?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 20:01","pubTimestamp":1780920082,"startTime":"0","endTime":"0","summary":"梯瓦制药（Teva Pharmaceutical）公布的数据显示，其Austedo®（氘代丁苯那嗪）片剂与Austedo XR®（氘代丁苯那嗪）缓释片剂，在迟发性运动障碍的治疗与护理方面取得了显著的长期进展。这些数据进一步证实了该药物在管理这一挑战性运动障碍中的持续疗效与价值，为患者提供了更稳定、持久的症状控制方案，有望改善长期治疗结局与生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4007","TEVA","LU2324357040.USD","BK4566","LU1983299246.USD","BK4584","BK4596","BK4559","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110985415","title":"Veru授予諾和諾德優先談判權，涉及恩諾博沙姆與任何諾和諾德GLP-1產品的聯合療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1110985415","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110985415?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 20:34","pubTimestamp":1780576456,"startTime":"0","endTime":"0","summary":"Veru Inc. 已授予诺和诺德一项优先谈判权，内容涉及将其药物恩诺博沙姆与诺和诺德旗下任何GLP-1产品相结合的联合疗法开发。此项协议为两家公司在代谢疾病治疗领域的潜在合作奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4007","BK4557","VERU","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121184893","title":"梯瓦製藥拓展歐洲生物類似藥版圖 推出阿柏西普生物類似藥Ahzantive®","url":"https://stock-news.laohu8.com/highlight/detail?id=1121184893","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121184893?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 20:32","pubTimestamp":1780576370,"startTime":"0","endTime":"0","summary":"梯瓦制药正通过在欧洲市场推出阿柏西普（Aflibercept）生物类似药Ahzantive®，进一步扩大其在该地区的生物类似药产品组合。该药物是眼科重磅药物Eylea®的生物类似药版本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4588","BK4559","BK4007","BK4566","LU2324357040.USD","BK4557","LU1983299246.USD","BK4596","BK4585","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199926780","title":"曼恩凱德生物醫療進入數據密集開發階段：完成Inhlo-1研究1B期隨機化並啓動Nintedanib DPI針對IPF患者的Inhlo-2試驗2期首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1199926780","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199926780?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 18:11","pubTimestamp":1780481465,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗正步入一个数据密集的开发阶段。公司已成功完成其Inhlo-1研究1B期的患者随机化工作，并启动了针对特发性肺纤维化患者的Nintedanib干粉吸入剂Inhlo-2试验2期研究，首位患者已完成入组。与此同时，Inhlo-2试验2期的启动将更深入地探索Nintedanib DPI在IPF患者中的疗效与作用机制。随着这些临床研究的推进，曼恩凯德有望在未来获得大量宝贵的临床数据，为药物的进一步开发提供坚实依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640547965","title":"足球——國際足聯推出全球計劃，旨在提升女足運動員的健康水平和競技表現","url":"https://stock-news.laohu8.com/highlight/detail?id=2640547965","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640547965?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 00:37","pubTimestamp":1780331841,"startTime":"0","endTime":"0","summary":"足球——国际足联推出全球计划，旨在提升女足运动员的健康水平和竞技表现Lori Ewing路透英格兰曼彻斯特6月1日 - 国际足联正加大力度，致力于消除体育界最顽固的盲点之一——对女运动员研究不足的问题。为此，国际足联推出了一项新的全球教育计划，旨在为从基层到精英层级的女子足球提供更完善的支持。国际足联指出，尽管女子足球的受欢迎程度和参与人数激增，但塑造训练和恢复方案的大部分研究仍基于男性数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nL4T4291EX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4584","VERU","BK4007","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639167900","title":"熱門話題-FDA批准用於兒童的吸入式胰島素後，MannKind股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2639167900","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639167900?lang=zh_tw&edition=fundamental","pubTime":"2026-05-30 00:51","pubTimestamp":1780073481,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4T4261JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4139","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639679265","title":"美國食品藥品監督管理局批准曼恩康德公司用於兒童的吸入式胰島素","url":"https://stock-news.laohu8.com/highlight/detail?id=2639679265","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639679265?lang=zh_tw&edition=fundamental","pubTime":"2026-05-30 00:35","pubTimestamp":1780072543,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准曼恩康德公司用于儿童的吸入式胰岛素路透5月29日 - 美国食品药品监督管理局已批准将 曼恩康德公司（MannKind）的 MNKD.O 吸入式速效胰岛素的适用范围扩大至患有糖尿病的儿童，为18岁以下的患者提供了一种无针治疗方案，该公司周五表示。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4S4261IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143603220","title":"曼恩凱德生物醫療宣佈FDA批准Afrezza®，首個且唯一用於6歲及以上糖尿病兒童及青少年的吸入式餐時胰島素","url":"https://stock-news.laohu8.com/highlight/detail?id=1143603220","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143603220?lang=zh_tw&edition=fundamental","pubTime":"2026-05-30 00:30","pubTimestamp":1780072234,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，其产品Afrezza®已获得美国食品药品监督管理局的批准。该药物成为首个且唯一获批用于6岁及以上糖尿病儿童及青少年群体的吸入式餐时胰岛素。这一里程碑式的批准为这一特定年龄段的患者提供了一种全新的胰岛素给药方式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190416573","title":"曼恩凱德生物醫療獲FDA解除對Afrezza的上市後要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1190416573","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190416573?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 20:39","pubTimestamp":1779971957,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，美国食品药品监督管理局（FDA）已于2026年5月27日解除了对曼恩凯德生物医疗（MannKind）旗下产品Afrezza的上市后要求。此举标志着该公司在满足监管机构对该吸入式胰岛素产品的特定条件方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}